Skip to main content

Table 1 Subject demographics

From: Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells

  Peripheral blood CD8 Pulmonary CD8
COPD(17) S(10) HNS(7) COPD(6) S(4)
Age (yrs) 62.6 (45–72) 51.9 (38–75) 55.8 (44–69) 58.7 (43–73) 61.3 (50–68)
Male/Female 14/3 3/7* 2/5* 5/1 4/0
FEV1 (L) 1.5 (0.09) 3.0 (0.34)* 3.06 (0.35)* 1.75 (0.24) 3.11 (0.56)*
FEV1 % predicted 53.6 (3.5) 96.1 (3.83)* 99.6 (6.23)* 58.7 (9.7) 104.4 (11.8)*
FEV1: FVC (%)* 47.2 (2.8) 79.1 (1.89)* 79.1 (2.87)* 58.9 (8.4) 76.7 (8.9)*
Current Smoker 8 5 0* 3 4
Smoking History (pkyr) 42 (5.3) 17.6 (4.0)* 0* 42.4 (15.5) 36 (25.7)
ICS 10 0* 0* 2 0*
  1. Data presented as mean (SD) or median (range). Data for all experiments are combined in this table. There were no significant differences between demographics of subsets of volunteers for individual experiments. PBMC samples were paired with peripheral blood CD8 cells. Therefore separate demographics for PBMCs not displayed. Statistically significant differences between COPD and other patient groups are indicated by *p < 0.05. COPD: chronic obstructive pulmonary disease; S: smoker with normal lung function; HNS: healthy non-smoker; FEV1: Forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids